Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Neurorehabilitation for other neurologic disorders.
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.
FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells.
Elevation of Ser9 phosphorylation of GSK3β is required for HERV-W env-mediated BDNF signaling in human U251 cells.
MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Vitamin D-binding protein and vitamin D status of black Americans and white Americans.
Please mind the gap: axonal transport deficits in multiple sclerosis neurodegeneration.
Riluzole increases glutamate uptake by cultured C6 astroglial cells.
Cyclophosphamide therapy in pediatric multiple sclerosis.
Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway.
CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord.
Clinical analysis of the etiology of optic neuritis in patients at different ages in china.
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study.
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
In Vivo Brain MR Imaging at Subnanoliter Resolution: Contrast and Histology.
Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis.
The refinement of genetic predictors of multiple sclerosis.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Impact of Depression, Fatigue and Disability on Quality of Life in Chinese Patients with Multiple Sclerosis.

Pages